Forskolin compared with beclomethasone for prevention of asthma attacks: A single-blind clinical trial

Journal of International Medical Research

Volumn 38, Issue 2, 2010, Pages 661-668

  Huerta, M ^a   Urzua Z ^a   Trujillo, X ^a   Gonzalez Sanchez R ^b   Trujillo Hernandez B ^b  

^a UNIVERSIDAD DE COLIMA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Adults; Asthma; Beclomethasone; Complimentary and alternative medicine (CAM); Forskolin; Prevention

Indexed keywords

BECLOMETASONE; FORSKOLIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MORNING DOSAGE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77953713595     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800229     Document Type: Article

References (40)

1. Hansel TT, Barnes PJ: Novel drugs for treating asthma. Curr Allergy Asthma Rep 2001; 1: 164-173.
2. Frieri M: Advances in the understanding of allergic asthma. Allergy Asthma Proc 2007; 28: 614-619.
3. Rizzo MC, Solé D, Naspitz CK: Corticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: safety vs. efficacy. Allergol Immunopathol 2007; 35: 197-208.
4. Huntley A, Ernst E: Herbal medicines for asthma: a systematic review. Thorax 2000; 5: 925-929.
5. Passalacqua G, Bousquet PJ, Carlsen KH, et al ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma.J Allergy Clin Immunol 2006; 117: 1054-1062.
6. Kreutner W, Chapman RW, Gulbenkian A, et al Bronchodilator and antiallergy activity of forskolin. Eur J Pharmacol 1985; 111: 1-8.
7. Kaik G, Witte PU: Protective effect of forskolin in acetylcholine provocation in healthy probands. Comparison of 2 doses with fenoterol and placebo. Wien Med Wochenschr 1986; 136: 637-641 [in German].
8. Bauer K, Dietersdorfer F, Sertl K, et al: Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther 1993; 53: 76-83.
9. Seamon KB, Daly JW: Forskolin: a unique diterpene activator of cyclic AMP-generating systems. Cyclic Nuckotide Res 1981; 7: 201-224.
10. de Souza NJ, Dohadwalla AN, Reden J: Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 1983; 3: 201-219.
11. Tsukawaki M, Suzuki K, Suzuki R, et al: Relaxant effects of forskolin on guinea pig tracheal smooth muscle. Lung 1987; 165: 225-237.
12. Yousif MH, Thulesius O: Forskolin reverses tachyphylaxis to the bronchodilator effects of salbuiamol: an in vitro study on isolated guinea-pig trachea.J Pharm Pharmacol 1999; 51: 181-186.
13. Thorneloe KS, Nelson MT: Ion channels in smooth muscle: regulators of intracellular calcium and contractility. Can J Physiol Pharmacol 2005; 83: 215-242.
14. González-Sánchez R, Trujillo X, Trujillo-Hernádndez B, et al: Forskolin compared with cromoglycate for prevention of acute asthma.J Int Med Res 2006; 34: 200-207.
15. National Heart, Lung and Blood Institute: National Asthma Education and Prevention Program: Highlights of the Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma.J Allergy Clin Immunol 2007; 120(5 suppl): S94-S138.
16. Fleiss JL: Statistical Methods for Rates and Proportions, 2nd edn. New York: John Wiley, 1981; pp 44-45.
17. Penn RB, Panettieri RA Jr, Benovic JL: Mechanisms of acute desensitization of the β2AR-adenylyl cyclase pathway in human airway smooth muscle. Am J Respir Cell Mol Biol 1998; 19: 338-348.
18. Danahay H, Atherton H, Jones G, et al: Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 282: L226-L236.
19. Fuller RW, O'Malley G, Baker AJ, et al: Human alveolar macrophage activation: inhibition by forskolin but no beta-adrenoreceptor stimulation of phosphodiesterase inhibition. Pulm Pharmacol 1988; 1: 101-106.
20. ForsLean®: Toxicological Studies (performed at the Indian Institute of Toxicology, Pune, India). Piscataway: USA, 2000 (available at: http://www.forslean.com/toxicogical.htm).
21. De Souza NJ: Industrial development of traditional drugs: the forskolin example. A mini-review. J Ethnopharmacol 1993; 38: 177-180.
22. Siegl AM, Daly JW, Smith JB: Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21: 680-687.
23. Adnot S, Desmier M, Ferry N, et al: Forskolin (a powerful inhibitor of human platelet aggregation). Biochem Pharmacol 1982; 31: 4071-4074.
24. Iwatsubo K, Tsunematsu T, Ishikawa Y: Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. Experf Opin Ther Targets 2003; 7: 441-451.
25. Onda T, Hashimoto Y, Nagai M, et al: Type-specific regulation of adenylyl cyclase. J Blot Chem 2001; 276: 47785-47793.
26. Toya Y, Schwencke C, Ishikawa Y: Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol 1998; 30: 97-108.
27. Hersey SJ, Owirodu A, Miller M: Forskolin stimulation of acid and pepsinogen secretion by gastric glands. Biochim Biophys Acta 1983; 755: 293-299.
28. Kashiwagi A, Huecksteadt TP, Foley JE: The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J Biol Chem 1983; 258: 13685-13692.
29. Morris DI, Speicher LA, Ruoho AE, et al: Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry 1991; 30: 8371-8379.
30. + channels is independent of adenylate cyclase activation. Science 1988; 240: 1652-1655.
31. Wachtel H, Löschmann PA: Effects of forskolin and cyclic nucleotides in animal models predictive of antidepressant activity: interactions with rolipram. Psychopharmacology (Berlin) 1986; 90: 430-435.
32. Fitzgerald DJ, Speir WA, Callahan LA: Office evaluation of pulmonary function. Beyond the numbers. Am Fam Physician 1996; 54: 525-534.
33. Zainudin B: Steroid therapy in obstructive airway diseases. Respirology 1997; 2: 17-31.
34. Fantidis P, Fernández-Ortiz A, Aragoncillo P, et al Effect of cAMP on the function of endothelial cells and fibromuscular proliferation after the injury of the carotid and coronary arteries in a porcine model. Rev Esp Cardiol 2001; 54: 981-989 [in Spanish].
35. Tanizawa M, Watanabe T, Kume H, et al: Phosphodiestase IV inhibitors synergistically potentiate relaxation induced by forskolin in guinea-pig trachea. Clin Exp Pharmacol Physlol 1998; 25: 114-119.
36. Agarwal KC, Parks RE: Forskolin: a potential antimetastatic agent. Int J Cancer 1983; 32: 801-804.
37. Barrels SP, Lee SR, Nuefeld AH: Forskolin stimulates cyclic AMP synthesis, lowers intraocular pressure and increases outflow facility in rabbits. Curr Eye Res 1982; 2: 673-681.
38. Bristow MR, Ginsburg R, Strosberg A, et al: Pharmacology and inotropic potential of forskolin in the human heart. J Clln Invest 1984; 74: 212-223.
39. Kramer W: Effects of forskolin on left ventricular function in dilated cardiomyopathy. Arzneimittelforschung 1987; 37: 364-367.
40. Schorlemmer HU: Forskolin for immune stimulation. Chem Abstr 1985; 102: 1009.